journal article·2025-12-31Open access

Vitamin D3 loaded polycaprolactone nanoparticles enhance the expression of the antimicrobial peptide cathelicidin in macrophages

Prince N. Dlozi, Rami Ahmed, Star Khoza, Admire Dube

Abstract

Tuberculosis (TB), primarily caused by Mycobacterium tuberculosis, remains a global health burden. Current antibiotic treatments are limited by adverse effects, poor adherence, and drug resistance, necessitating new therapeutic approaches. Recent studies highlight the role of vitamin D3 (VD3) in enhancing host immune responses against the mycobacterium via cathelicidin (an antimicrobial peptide) and autophagy activation. In this study, VD3-loaded poly-ƹ-caprolactone (PCL) nanoparticles (NPs) were synthesized to enhance cathelicidin expression in macrophages. NPs containing cholecalciferol, calcifediol, and calcitriol were synthesized using an emulsification solvent-evaporation technique. Average sizes of synthesized NPs ranged from 304.7 to 458.7 nm, with polydispersity index (PDI) and zeta potential (ZP) ranging from 0.103 to 0.257 and −17.3 to −7.47 mV, respectively. Encapsulation efficiencies were 9.68%, 10.99%, and 19.28% for cholecalciferol, calcifediol, and calcitriol, respectively. VD3-encapsulated NPs stimulated a dose-dependent increase in cathelicidin expression in THP-1 macrophages. Encapsulated calcifediol and calcitriol (100 ng/ml) induced the expression of 243.46 ng/ml ± 4.55 ng/ml and 396.67 ng/ml ± 25.24 ng/ml of cathelicidin, respectively, which was significantly higher than that induced by the free drugs. These findings suggest that NP encapsulation may offer a more efficient approach to using vitamin D3 for inducing cathelicidin expression as a host-directed treatment for TB.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Antimicrobial Peptides and Activities · Vitamin D Research Studies · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy, University of the Western Cape

Funding

National Institute of Allergy and Infectious Diseases · National Research Foundation (NRF) of South Africa

References (68)

Show source-provided references
1. 10.26717/BJSTR.2023.50.00800210.26717/BJSTR.2023.50.008002 ↗
2. 10.3390/ijms2406520210.3390/ijms24065202 ↗
3. World Health Organization. Global Tuberculosis Report 2024. Geneva World Health Organization; 2024.
4. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva; 2022.
5. 10.1007/978-3-319-19132-4_310.1007/978-3-319-19132-4_3 ↗
6. 10.1002/cpt.226110.1002/cpt.2261 ↗
7. 10.1371/journal.pmed.100259510.1371/journal.pmed.1002595 ↗
8. 10.1101/cshperspect.a01786310.1101/cshperspect.a017863 ↗
9. 10.1016/j.ijid.2014.12.00110.1016/j.ijid.2014.12.001 ↗
10. 10.3389/fcimb.2021.63336010.3389/fcimb.2021.633360 ↗
11. 10.1371/journal.pone.0138340.e013834010.1371/journal.pone.0138340.e0138340 ↗
12. 10.1016/j.ejpb.2016.11.02610.1016/j.ejpb.2016.11.026 ↗
13. Behera AK, Shah S, Mantry S, et al. Characterization and pharmacokinetics of rifampicin loaded poly-ε-caprolactone nanoparticles for oral administration. Int J Innov Pharma Sci Res. 2013;1:71–82.
14. 10.1186/s12645-014-0008-410.1186/s12645-014-0008-4 ↗
15. 10.1080/21505594.2018.153659810.1080/21505594.2018.1536598 ↗
16. 10.1038/s12276-019-0290-710.1038/s12276-019-0290-7 ↗
17. 10.1016/j.tube.2012.05.00410.1016/j.tube.2012.05.004 ↗
18. 10.1111/j.1462-5822.2011.0164410.1111/j.1462-5822.2011.01644 ↗
19. 10.1016/j.ijpharm.2017.04.07410.1016/j.ijpharm.2017.04.074 ↗
20. 10.1016/j.jdermsci.2013.01.01110.1016/j.jdermsci.2013.01.011 ↗
21. 10.1016/b978-0-12-386960-9.00013-710.1016/b978-0-12-386960-9.00013-7 ↗
22. 10.1007/s12016-009-8150-110.1007/s12016-009-8150-1 ↗
23. 10.1016/j.chom.2009.08.00410.1016/j.chom.2009.08.004 ↗
24. 10.3390/ph1605063710.3390/ph16050637 ↗
25. 10.5772/6451610.5772/64516 ↗
26. 10.1016/j.jsbmb.2017.07.02710.1016/j.jsbmb.2017.07.027 ↗
27. 10.3945/ajcn.2010.2941110.3945/ajcn.2010.29411 ↗
28. 10.1007/s10875-009-9277-910.1007/s10875-009-9277-9 ↗
29. 10.1016/j.jsbmb.2010.03.03410.1016/j.jsbmb.2010.03.034 ↗
30. 10.1016/j.biopha.2022.11318910.1016/j.biopha.2022.113189 ↗
31. 10.1093/ajcn/88.2.582S10.1093/ajcn/88.2.582S ↗
32. 10.1194/jlr.r03153410.1194/jlr.r031534 ↗
33. 10.3390/ph1308016010.3390/ph13080160 ↗
34. 10.1080/10408398.2012.68889710.1080/10408398.2012.688897 ↗
35. 10.1007/s11095-012-0949-410.1007/s11095-012-0949-4 ↗
36. 10.1016/j.foodchem.2014.09.05410.1016/j.foodchem.2014.09.054 ↗
37. 10.3390/pharmaceutics1204037110.3390/pharmaceutics12040371 ↗
38. 10.1016/B978-0-12-819811-7.00007-210.1016/B978-0-12-819811-7.00007-2 ↗
39. 10.1002/smll.20120139010.1002/smll.201201390 ↗
40. 10.1016/s1734-1140(12)70901-510.1016/s1734-1140(12)70901-5 ↗
41. 10.1021/bm900266r10.1021/bm900266r ↗
42. 10.1021/acs.chemrev.3c0070510.1021/acs.chemrev.3c00705 ↗
43. 10.3144/expresspolymlett.2021.5410.3144/expresspolymlett.2021.54 ↗
44. Satish KV, Kumar GS, Jayaveera KN. Preparation of poly-ƹ-caprolactone nanoparticles by double emulsion solvent evaporation technique for ocular delivery. J Pharm Chem. 2014;8(3):7–14.
45. 10.1016/s0378-5173(02)00058-310.1016/s0378-5173(02)00058-3 ↗
46. 10.1016/s0169-409x(97)00049-510.1016/s0169-409x(97)00049-5 ↗
47. 10.4236/jbnb.2016.7201110.4236/jbnb.2016.72011 ↗
48. 10.2147/IJN.S4310.2147/IJN.S43 ↗
49. 10.1590/s1984-8250201100010001210.1590/s1984-82502011000100012 ↗
50. Rahman A, Rahman MM, Hossain MS, et al. A simple and alternative uv spectrometric method for the estimation of vitamin D3. Microbial Bioactives. 2019;2(1):E098–E105.
51. 10.3389/fcimb.2022.87577210.3389/fcimb.2022.875772 ↗
52. 10.1210/en.2017-0057810.1210/en.2017-00578 ↗
53. Freshney R, I, Capes-Davis A. Freshney’s culture of animal cells: a manual of basic technique and specialized applications. Wiley-Blackwell. 2021;8:704–712.
54. 10.1016/j.cimid.2018.09.00110.1016/j.cimid.2018.09.001 ↗
55. 10.1098/rsif.2008.0009.focus10.1098/rsif.2008.0009.focus ↗
56. 10.1016/j.jbc.2021.10120910.1016/j.jbc.2021.101209 ↗
57. 10.1007/s00396-014-3464-910.1007/s00396-014-3464-9 ↗
58. 10.1016/j.colsurfa.2016.12.02910.1016/j.colsurfa.2016.12.029 ↗
59. 10.1039/c8sm00780b10.1039/c8sm00780b ↗
60. 10.1016/j.ultramic.2017.07.00110.1016/j.ultramic.2017.07.001 ↗
61. 10.1016/S0168-3659(01)00230-910.1016/S0168-3659(01)00230-9 ↗
62. ISO 10993-5. 2009. Biological evaluation of medical devices—Part 5: tests for in vitro cytotoxicity. Standardization IOf ed. vol. ISO 10993-5. Switzerland.
63. 10.1088/1748-605X/aca73610.1088/1748-605X/aca736 ↗
64. 10.1186/s12951-016-0174-010.1186/s12951-016-0174-0 ↗
65. 10.1016/j.vaccine.2014.08.07510.1016/j.vaccine.2014.08.075 ↗
66. 10.33176/AACB-20-0000610.33176/AACB-20-00006 ↗
67. Pinzone MR, Diros M, Celesia BM, et al. LPS and HIVgp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals. Eur Rev Med Pharmacol Sci. 2013;17:1938–1950.
68. 10.3390/pharmaceutics1302019110.3390/pharmaceutics13020191 ↗